Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation drug candidates when used in the long term tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringheim, Garth E., Wampole, Matthew, Oberoi, Kinsi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595937/
https://www.ncbi.nlm.nih.gov/pubmed/34803999
http://dx.doi.org/10.3389/fimmu.2021.662223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595937/
https://www.ncbi.nlm.nih.gov/pubmed/34803999
http://dx.doi.org/10.3389/fimmu.2021.662223

Ejemplares similares